Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

Phase 2

Terminated

• Conditions: Peripheral Vascular Disease

• Registration Number: NCT00067041
• Lead Sponsor: United Therapeutics

Brief Summary

Approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted in the hospital and on an out-patient basis. The study will be conducted at multiple centers.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-03
• Study First Submitted: 2003-08-08
• Study First Submitted QC: 2003-08-12
• Study First Posted: 2003-08-13
• Primary Completion: 2003-12
• Study Completion: 2003-12
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-05
• Last Update Posted: 2013-03-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (4)

Southern Illinois University School of Medicine; 🇺🇸 Springfield, Illinois, United States

University of Massachusetts Memorial Health Center; 🇺🇸 Worcester, Massachusetts, United States

Vascular Institute Albany Medical College; 🇺🇸 Albany, New York, United States

Oregon Health Sciences University; 🇺🇸 Portland, Oregon, United States